Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 4018-4020

  Clavel, C ^a   Peytavin, G ^b   Tubiana, R ^c   Soulie C ^c   Courbon, E ^b   Crenn Hebert, C ^d,e   Ichou, H ^d   Blanc, C ^c   Schneider, L ^c   Katlama, C ^c   Marcelin, A G ^c   Mandelbrot, L ^d,e  

^a Infectious Diseases   (France)

^b BICHAT HOSPITAL   (France)

^c INSERM   (France)

^d HÔPITAL LOUIS MOURIER   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ETRAVIRINE; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG PENETRATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; UTERINE CERVIX; UTERINE CERVIX MUCUS; VIRUS REPLICATION; VIRUS SHEDDING;

ADULT; ANTI-HIV AGENTS; CERVIX UTERI; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PYRIDAZINES; RNA, VIRAL; VAGINA; VIRUS REPLICATION;

EID: 84862575892     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06474-11     Document Type: Article

References (12)

1. Clavel C, et al. 2011. Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 Study). Antimicrob. Agents Chemother. 55:3018-3021.
2. Cu-Uvin S, et al. 2010. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 24:2489-2497.
3. Cu-Uvin S, et al. 2000. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 14:415-421.
4. De Pasquale MP, et al. 2003. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 34:37-44.
5. Dumond JB, et al. 2009. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 51:546-553.
6. Dumond JB, et al. 2007. Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis. AIDS 21:1899-1907.
7. Harms G, Kunz A, Karcher H, Mugenyi K, Kurowski M. 2005. Nevirapine concentration in cervicovaginal and oropharyngeal secretions after single-dose administration to the mother. Antivir. Ther. 10:777.
8. Kemal KS, et al. 2007. HIV-1 drug resistance in variants from the female genital tract and plasma. J. Infect. Dis. 195:535-545.
9. Kwara A, et al. 2008. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin. Infect. Dis. 46:719-725.
10. Patterson K, Jennings S, Falcon R, Mrus J, Kashuba A. 2011. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob. Agents Chemother. 55:1120-1122.
11. Sheth A, et al. 2011. Genital secretions of HIV-1 infected women on effective antiretroviral therapy contain high drug concentrations and low amounts of cell-free virus. 6th IAS Conf. HIV Pathog. Treat., abstr. MOAC0204.
12. Si-Mohamed A, et al. 2000. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J. Infect. Dis. 182:112-122.